Company / Capital Returned to Shareholders
10x Genomics, Inc. Capital Returned to Shareholders History
FY2017-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$80.0K
FY2017
5-year range
-
FY2017-FY2017
Trend
-
vs FY2016
Sector context
#93 of 103
Health Care
What the data says
Among 103 Health Care companies, 10x Genomics, Inc. is in the bottom 10% for capital returned to shareholders.
Based on SEC 10-K filings.
$80,000 in FY2017.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 103This company $80.0K Sector average $721.8M
▼
-100.0% below sector average
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $80.0K | - |
As of FY2017 · SEC 10-K · Updated Feb 28, 2026